The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bromodomain and extra-terminal (BET) inhibitor INCB057643 in patients with relapsed or refractory myelofibrosis (MF) and other advanced myeloid neoplasms: A phase 1 study.
 
Justin M. Watts
Consulting or Advisory Role - Aptose Biosciences; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; Rafael Pharmaceuticals; Reven Pharmaceuticals; Rigel; SERVIER
Research Funding - Immune System Key; Takeda
 
Alessandro M. Vannucchi
Consulting or Advisory Role - AbbVie; AOP Orphan Pharmaceuticals; Blueprint Medicines; GlaxoSmithKline; Incyte; Novartis; Roche
Speakers' Bureau - AbbVie; AOP Orphan Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Incyte; Novartis
 
Anthony Hunter
Consulting or Advisory Role - Sierra Oncology
 
Brandon McMahon
Consulting or Advisory Role - GlaxoSmithKline; PharmaEssentia
 
Srinivas Kiran Tantravahi
Honoraria - Abbvie; CTI BioPharma Corp; Karyopharm Therapeutics; MorphoSys; Novartis
Consulting or Advisory Role - Abbvie; CTI BioPharma Corp; Karyopharm Therapeutics; MorphoSys; Novartis
Research Funding - Karyopharm Therapeutics
 
Alessandra Iurlo
Honoraria - AOP Health; BMS GmbH & Co. KG; GlaxoSmithKline; Incyte; Novartis; Pfizer
Consulting or Advisory Role - AOP Health; Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Novartis; Pfizer
 
Blanca Xicoy
No Relationships to Disclose
 
Francesca Palandri
Honoraria - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
Consulting or Advisory Role - Abbvie; Amgen; AOP Orphan Pharmaceuticals; Celgene; Celgene/Bristol-Myers Squibb; CTI; GlaxoSmithKline; Grifols; Karyopharm Therapeutics; MorphoSys; Novartis; Sierra Oncology; SOBI
 
Emma Searle
Honoraria - AbbVie; Janssen
Consulting or Advisory Role - Bristol-Myers Squibb; DarkBlue Therapeutics; Sanofi and Shattuck Labs
 
Brandi Reeves
Honoraria - Bristol-Myers Squibb; Incyte; PharmaEssentia
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; Cogent Biosciences; CTI BioPharma Corp; GlaxoSmithKline; Incyte; Ionis Pharmaceuticals; Jubilant Therapeutics; Karyopharm Therapeutics; Morphic Therapeutic; MorphoSys; Novartis; Pharmaessentia
Consulting or Advisory Role - Ono Pharmaceutical; Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Geron (Inst); Incyte (Inst); Ionis Pharmaceuticals (Inst); Janssen (Inst); Kartos Therapeutics (Inst); Karyopharm Therapeutics (Inst); MorphoSys (Inst); Telios (Inst)
 
Rosa Ayala Diaz
Consulting or Advisory Role - Incyte; Novartis
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Novartis
 
Anna B. Halpern
Consulting or Advisory Role - Abbvie; Agios; Notable labs
Research Funding - Bayer (Inst); disc medicine (Inst); Gilead/Forty Seven (Inst); Imago Pharma (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Karyopharm Therapeutics (Inst)
 
Xuejun Chen
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Lea Micaletti Burke
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Feng Zhou
Employment - Incyte
Leadership - Incyte
 
Fred Zheng
Employment - Incyte
Stock and Other Ownership Interests - Incyte
 
Pankit Vachhani
Consulting or Advisory Role - Abbvie; Amgen; Blueprint Medicines; Cogent Biosciences; CTI BioPharma Corp; Genentech/Roche; GlaxoSmithKline; Incyte; Karyopharm Therapeutics; Merck; MorphoSys; Novartis; Pfizer; Stemline Therapeutics
Speakers' Bureau - Blueprint Medicines; Incyte
Research Funding - Abbvie (Inst); Amgen (Inst); Astex Pharmaceuticals (Inst); Blueprint Medicines (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Gilead/Forty Seven (Inst); Incyte (Inst); Kartos Therapeutics (Inst); Seagen (Inst); Takeda (Inst)